AbbVie Inc. $ABBV Stock Bought by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 46.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 22,000 shares of the company’s stock after buying an additional 7,000 shares during the period. AbbVie accounts for approximately 3.6% of Sivik Global Healthcare LLC’s portfolio, making the stock its 5th biggest holding. Sivik Global Healthcare LLC’s holdings in AbbVie were worth $5,755,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of ABBV. Compass Financial Group INC SD raised its position in shares of AbbVie by 15.3% in the 3rd quarter. Compass Financial Group INC SD now owns 1,648 shares of the company’s stock worth $431,000 after purchasing an additional 219 shares during the last quarter. Sax Wealth Advisors LLC grew its position in AbbVie by 40.5% during the 3rd quarter. Sax Wealth Advisors LLC now owns 16,271 shares of the company’s stock valued at $4,256,000 after purchasing an additional 4,692 shares during the last quarter. Fermata Advisors LLC grew its position in AbbVie by 23.7% during the 3rd quarter. Fermata Advisors LLC now owns 1,124 shares of the company’s stock valued at $294,000 after purchasing an additional 215 shares during the last quarter. Haven Capital Group Inc. increased its stake in AbbVie by 1.2% during the 3rd quarter. Haven Capital Group Inc. now owns 22,383 shares of the company’s stock valued at $5,855,000 after purchasing an additional 264 shares in the last quarter. Finally, Burkett Asset Management Ltd bought a new stake in AbbVie during the 3rd quarter valued at about $498,000. Institutional investors own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Fresh clinical and regulatory developments are strengthening AbbVie’s growth narrative. Phase 3 data for SKYRIZI and RINVOQ in Crohn’s disease, along with FDA Breakthrough Therapy Designations for temab-A in colorectal and lung cancer, could expand the company’s long-term commercial opportunities. Early obesity data also add potential upside to the pipeline. AbbVie Could Be 44% Below Fair Value on Fresh Pipeline Wins
• Positive Sentiment: Long-term data presented at ACG 2026 continue to support the durability and growth prospects of SKYRIZI and RINVOQ. Analysts expect the two therapies to offset part of Humira’s revenue erosion and drive third-quarter top-line growth. AbbVie Highlights Long-Term SKYRIZI and RINVOQ Data
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $280 price target, indicating continued confidence in AbbVie’s earnings outlook despite limited near-term upside at current levels.
• Neutral Sentiment: Recent coverage highlights AbbVie as an attractive income stock after market weakness pushed its dividend yield higher. That may support defensive and income-oriented demand, though the yield increase also reflects recent selling pressure. High-Yield Dividend Stocks
• Negative Sentiment: At a lofty valuation following a substantial rally, investors may be taking profits while assessing whether SKYRIZI and RINVOQ can fully replace Humira sales. Rising competition in immunology and the stock’s limited analyst-implied upside are additional near-term headwinds. Will SKYRIZI and RINVOQ Drive AbbVie’s Top-Line Growth?

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. BNP Paribas Exane upped their target price on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Morgan Stanley raised their price target on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Guggenheim restated a “buy” rating and issued a $288.00 price objective on shares of AbbVie in a report on Friday. Weiss Ratings raised AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday. Finally, BMO Capital Markets increased their target price on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $277.18.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by company insiders.

AbbVie Trading Down 1.7%

NYSE:ABBV traded down $4.77 during trading hours on Tuesday, reaching $276.35. The company had a trading volume of 2,013,791 shares, compared to its average volume of 6,391,498. The firm has a market cap of $488.26 billion, a price-to-earnings ratio of 78.08, a PEG ratio of 1.26 and a beta of 0.24. The firm’s 50 day moving average price is $259.79 and its 200-day moving average price is $237.39. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $283.43.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. AbbVie’s dividend payout ratio is presently 195.48%.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.